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Since their discovery twenty years ago and prospective isolation a decade later, neural stem cells (NSCs),
their progenitors, and differentiated cell derivatives along with other stem-cell based strategies have
advanced steadily toward clinical trials, spurred by the immense need to find reparative therapeutics for
central nervous system (CNS) diseases and injury. Current phase I/II trials using stem cells in the CNS are
the vanguard for the widely anticipated next generation of regenerative therapies and as such are pioneering
the stem cell therapy process. While translation has typically been the purview of industry, academic
researchers are increasingly driven to bring their findings toward treatments and face challenges in knowl-
edge gap and resource access that are accentuated by the unique financial, manufacturing, scientific, and
regulatory aspects of cell therapy. Solutions are envisioned that both address the significant unmet medical
need and lead to increased funding for basic and translational research.Introduction
Stem cell therapies are a new medical frontier. Pioneering work
using hematopoietic stem cells in therapeutic settings has
generated the precedent, and the recent scientific advances in
stem cell biology, brain plasticity, genomics, and neuroimaging
indicate that transformative changes lie ahead for repairing the
CNS. These advances, supported by animal experiments that
indicate some CNS damage may be preventable or reversible
by stem cell-based approaches, along with the limited self-initi-
ated reparative ability of the CNS and the enormous social
burden of neurological disease and injury, make this system
a prime target for regenerative therapies. Translation, by which
we mean advancing scientific discoveries from the laboratory
into practical applications for patient benefit, i.e., ‘‘bench to
bedside,’’ requires a comprehensive collaborative team ap-
proach: research scientists and clinicians must work closely
with regulatory agencies, patient advocacy groups, ethics
bodies, cell manufacturing facilities, and industry to achieve
the quality of studies and necessary funding to ensure success.
This requires new partnershipmodels for research in which tradi-
tional silos are broken down, translational teams are created,
and new mechanisms for effective hand-off from nonprofit to
for-profit are generated. Today many researchers in the stem
cell field have advanced their research far enough to attempt
clinical translation but lack the knowledge and wherewithal to
accomplish this arduous, expensive, and long-term task
(Figure 1). The significant hurdles needed to be surmounted
are illustrated in the analysis of the drug development process
(Figure 2). Despite these difficulties, steady progress toward
this goal is being made, spearheaded by industry, academicinstitutions, and nonprofit foundations in conjunction with a
recent focus by the National Institutes of Health (NIH) and the
Food and Drug Administration (FDA) in the U.S. on both transla-
tional research and regenerative medicine.
Here we describe the current status of, and pathways for, stem
cell-based CNS therapies, analyze the landscape of current
regulatory approved clinical trials, discuss the recent industry
trends and regulatory developments that can catalyze further
translational progress, and describe key issues and currently
available resources to facilitate more efficient translation of
promising research.
Stem Cell Sources for CNS Repair
Endogenous Sources
NSCs are the fundamental ancestor cells for the CNS (brain,
spinal cord, and retina), defined by their ability to self-renew
and produce all three major CNS cell types: neurons, astrocytes,
and oligodendrocytes. NSCs can be expanded substantially,
proliferating to produce cell lines that can differentiate into func-
tional neural cells after in vivo transplantation, demonstrating
tremendous promise for cell replacement and regenerative ther-
apies. NSCs are abundant in different regions of the fetal CNS
and are retained throughout life in restricted parts of the fore-
brain, notably the striatal subventricular zone and dentate gyrus
of the hippocampus. Human NSCs have been isolated from
donated fetal CNS tissue and can be defined by expression of
surface markers such as CD133 (Uchida et al., 2000), enabling
prospective enrichment, in vitro expansion using growth factors
such as FGF2 and EGF, and in-depth characterization. NSC
primary cell lines generated from human fetal CNS tissue,Neuron 70, May 26, 2011 ª2011 Elsevier Inc. 597
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Perspectivetypically around 8–18 weeks of gestation, are now the subject of
a number of clinical studies. Progenitor cells that arise from
human NSCs, such as glial-restricted progenitor cells (GRPs),
which produce oligodendrocytes and newmyelin, are also being
advanced toward the clinic (Goldman, 2011; Sandrock et al.,
2010). Other sources of neural cells showing promise in preclin-
ical studies include cells from nasal mucosa such as olfactory
ensheathing cells (Lindsay et al., 2010; Raisman and Li, 2007)
and skin-derived multipotent precursors (SKPs) (Fernandes
et al., 2008).
Multipotent stem and progenitor cells can also be extracted
from adult CNS regions where neurogenesis is not apparent,
then expanded and differentiated into neurons and glia in
culture, e.g., from adult murine spinal cord (Lowry et al., 2008;
Shihabuddin et al., 2000), human cortex (Schwartz et al.,
2003), and retina (Giannelli et al., 2010). These observations
also raise the exciting possibility that there are compartments
of endogenous stem cells that could be activated in situ to
promote repair. Certainly, gliogenic progenitor cells are present
throughout much of the CNS and can be coaxed to replace
lost oligodendrocytes or, in the case of injury or disease, canPreclinicalBasic Research
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598 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.proliferate and contribute to the proteo-
glycan rich astrocytic scar that inhibits
neuronal process regrowth. Hence con-
trolling endogenous stem and progenitor
cells to promote repair is another thera-
peutic avenue being actively pursued.
Pluripotent and Induced Sources
Human embryonic stem cells (hESCs)
offer an abundant source of NSCs that
can be further differentiated into a widevariety of functional neurons and glia. Induced pluripotent stem
cell (iPSC) lines, derived by reprogramming adult somatic cells
(e.g., fibroblasts) into an embryonic stem cell state, are a poten-
tial autologous source of NSCs (Hu et al., 2010), andwhile not yet
ready for clinical use, they are being explored as preclinical
disease models (Cundiff and Anderson, 2011). Another potential
source still in the early stages of investigation is the directed
differentiation of nonneural cells. For example, mouse fibroblasts
can be transdifferentiated into neurons via addition of specific
transcription factors in the neural pathway (Vierbuchen et al.,
2010) and resident glia into subtype-specific neurons (Heinrich
et al., 2011), which may prove valuable for CNS disease
modeling and conceivably for specific repair strategies.
Controversial Nonneural Sources of Neural Cells
There has been substantial controversy over claims that neural
cells can be derived from nonneural tissue such as bone marrow
with just environmental manipulations, including transplantation
into neural tissue. Rigorous scientific tests and lack of reproduc-
ibility have shown that such claims are unfounded, yet they
continue to plague the field: they are provided as rationale for
ongoing unregulated clinical trials and are used to persuaden
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Perspectivepatients to pay high sums for dubious and in some cases fraud-
ulent therapies. It is important to educate the public through
avenues such as the International Society for Stem Cell
Research (ISSCR) website A Closer Look at Stem Cell Treat-
ments (http://www.closerlookatstemcells.org) to help patients
make informed choices when contemplating stem cell therapies.
Pathway from Bench to Bedside
Impact
Potential CNS disease targets encompass a wide range of
neurological conditions with a variety of underlying causes.
These include stroke, traumatic brain injury (TBI), spinal cord
injury (SCI), multiple sclerosis (MS), age-related macular degen-
eration (AMD), Alzheimer’s disease (AD), Parkinson’s disease
(PD), epilepsy, brain cancer, and, perhaps further in the future,
mental disorders such as depression, autism, and schizo-
phrenia. Up to one billion people worldwide have neurological
disorders, accounting for 12% of global deaths (WHO, 2006).
As the population ages, the burden of age-related disorders
such as dementia, AD, PD, and AMD will also increase.
Translational Challenges for the CNS
The pathway of discovery, development, and implementation of
novel stem cell-based therapies for the CNS is being con-
structed and walked almost simultaneously. First-in-human
CNS stem cell trials pose specific ethical, regulatory, and clinical
challenges (Halme and Kessler, 2006). There are also numerousscientific and medical challenges that are unique to the CNS,
such as the impact of cell delivery in the host tissue; the need
to maintain existing connectivity and functionality while support-
ing new therapeutically relevant cell integration; overcoming
and/or utilizing the endogenous signals that impact the prolifer-
ation, migration, and fate of implanted cells; overcoming scar
formation at the site of injury; the functional and metabolic inter-
dependence of neurons, astrocytes, and oligodendrocytes and
its impact on donor cell survival and function; the complex neu-
roimmune axis that exists in the normal and diseased CNS; and
the challenge of modeling functional CNS recovery in animals.
Some examples of these challenges are discussed below.
Regulatory Considerations
Despite the specific challenges of targeting the CNS, the trans-
lation process for cellular therapies involves the same basic
steps as for drug therapies: clinical investigation must follow
an Investigational New Drug (IND) application in the US (Figure 3)
or similar regulatory filings in other countries. Human cellular
products such as stem and progenitor cells have unique require-
ments for characterization, manufacturing, and testing that are
regulated by a specific center within the FDA: the Center for Bio-
logics Evaluation and Research (CBER) and its Office of Cellular,
Tissue, and Gene Therapies (OCTGT).
If for real estate the mantra is ‘‘location, location, location,’’ for
making regulatory contacts the mantra is ‘‘early, early, early.’’
FDA representatives can provide guidance that represents yearsNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 599
Neuron
Perspectiveof work, saving time and money. A valuable review of the FDA
regulation of stem cell-based products outlines the safely issues,
pointing out that the FDA has over 20 years of experience with
cellular therapies to frame the work, but acknowledging that
the high proliferative potential and plasticity of stem cells leads
to additional concerns (Fink, 2009).
The process of submitting an IND application includes (1) a
recommended pre-IND meeting with the OCTGT for guidance
regarding preclinical study design, data analysis, clinical pro-
tocol schema, and necessary information for the IND application,
(2) submission of the complete IND package, and (3) IND review
(Figure 3). If a sponsor has not heard from the FDA after 30 days,
the trial can proceed; if there are safety concerns the FDA will
impose a ‘‘clinical hold’’ until issues are satisfactorily addressed.
Detailed information can be obtained from the FDA
website: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/
cfCFR/CFRSearch.cfm?CFRPart=312.
While this process sounds straightforward, in the case of CNS
stem cell therapies, the required documentation may run several
thousand pages (Figure 3). This can be partially attributed to
the fact that the lack of precedent for these first-in-human
stem cell trials requires a higher bar for preclinical demonstration
of efficacy and safety. The threshold for approval will vary
depending on the disease indication and risk/benefit ratio.
Additionally, if the cell product is genetically modified, separate
documentation (‘‘Appendix M’’) must be submitted to the NIH
Recombinant DNA Advisory Committee, established for the
protection of patients. Novel, unprecedented studies will prob-
ably require a public hearing by this committee, where a panel
of reviewers judge data presented and make recommendations
to the investigators and FDA. Finally, due to the lengthy process,
members of an FDA review panel may change over time, and
new issues may be raised at any time prior to trial initiation. As
new data are constantly being generated in this cutting-edge
field, criteria for IND acceptance are changing. Demonstration
of safety and feasibility in the first round of phase I stem cell-
CNS trials will probably have a great impact on facilitating future
IND filings.
Initiating the clinical study also requires Institutional Review
Board (IRB), InstitutionalBiosafetyCommittee (IBC), and typically
Stem Cell Research Oversight Committee (SCRO) approvals.
One of the barriers to the full use of NSCs in patient populations
is the reluctance of some IRBs to allow children to receive trans-
plants, although many CNS diseases are congenital and fatal in
childhood. This is probably due to the deaths of several gene
therapy patients under age 21, which has sensitized IRBs to the
public and legal issues involved. It is possible that instating
a centralized IRB, which has proved successful in oncology,
with a focus on CNS regenerative medicine could facilitate the
process, by providing expert guidance, e.g., on pediatric studies
and other aspects of regenerativeCNSapproaches to local IRBs.
Preclinical Animal Testing
Support for the clinical application of NSCs or other stem/
progenitor cells relies heavily on satisfactory proof of concept,
efficacy, and safety in animal models of human disease. The
FDA supports animal use aligned with the international commit-
ment to the 3R concept: reduce, refine, and replace, ensuring
that preclinical studies use reasonable numbers of animals and600 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.the optimummodel and, if possible, replace animals by alternate
means of testing. However, because no animal model entirely
recapitulates the complexity of human pathology and anatomy,
they are not always predictive of clinical outcomes. Furthermore,
measuring clinically relevant endpoints related to higher neural
functions such as cognition, learning, and memory is not always
feasible. Large animal models are sometimes regarded as a
needed second test species in which to confirm efficacy and/or
safety as well as short-term surgical feasibility studies. However,
these additional large animal studies are still xenogenic and very
expensive and, especially in the case of nonhuman primates,
require deep consideration for ethical use. Other ethical issues
include humanization of the animal CNS by neural cell transplan-
tation, which lead to additional scrutiny, for example, during
SCRO review. Finally, we note that the accurate repopulation of
immunodeficient rodent brains with NSCs and of the hematopoi-
etic system with human HSCs has led to FDA-authorized clinical
trials without the use of larger animals.
Characterization and Manufacture of Cell Product
for Transplantation
Defining a therapeutic stem cell product is challenging as cells
are not drugs with precise structures, but highly complex biolog-
ical entities for which sets of key markers and attributes are still
being defined. In the case of stem cell-derived RPE cells, for
example, which are moving rapidly toward the clinic, signature
gene expression patterns for the native tissue (Strunnikova
et al., 2010) can help construct biomarker-based definitions for
stem cell-derived RPE cells. While terminally differentiated cells
may be most valuable for some indications, in other cases
a precursor cell may be better suited for transplantation. For
example, in myelination disorders, progenitors from fetal versus
adult donors have distinct properties making them valuable for
different applications (Goldman, 2011). Therefore, it may be
necessary to define a specific stage of the lineage for optimum
results, underlining the need to perform thorough developmental
biology groundwork.
Once the final cell product is identified, the production of cell
lots for clinical use is a complex process that starts at the donor
(of cells and/or tissues) level and ends in the preparation steps
for product administration to the patient. Any activity along this
process may introduce elements that can pose potential risks
for adverse events. Cell-based therapies thus require stringent
safety assessments, particularly in relation to contamination
with infectious disease agents, animal product use, instability
due to extended expansion, and tumorigenicity. The FDA has
created guidance documents that address the various controls
and safeguards starting with donor eligibility, initial collection
of the source tissue under current good tissue practice (cGTP),
and subsequent manufacturing steps under current good
manufacturing practice (cGMP), which include tiered testing of
master and working cell banks, as well as release testing that
is done on the final cell product for transplantation (e.g., sterility,
purity, identity) (Burger, 2003; Rayment and Williams, 2010).
Therefore, production of a cGTP/cGMP cell bank is a significant
aspect of developing a cell therapy and investigators should not
underestimate the complexity, the time involved, and the scien-
tific and financial aspects of deriving cell doses for patient
testing. In addition, given that pivotal preclinical studies should
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Perspectivepreferentially be carried out using the intended clinical cell lot,
the need to implement cGMP/cGTP practices early may greatly
impact timelines and development costs.
Cell Fate and Tracking In Vivo
For therapies involving cell administration to theCNS, determina-
tion of cell migration and fate in real time and long term is ofmajor
interest as it relates to dosing, efficacy, optimization, and safety
concerns. Reporter genes used in preclinical studies are not
intended for the final cell product used in clinical trials. Therefore,
identification of donor cells in tissue at resection or autopsy can
be made if there is a gender mismatch between donor and
recipient or if there is a specific donor cell marker. A promising
cell-tracking method for monitoring NSCs involves preloading
with superparamagnetic iron oxide particles (SPIOs) just prior
to administration and subsequently tracking their distribution
over time by MRI. Preclinical studies in mice have demonstrated
the effective use of MRI to track iron-labeled NSCs (Guzman
et al., 2007; Thu et al., 2009), and the safe use of iron oxide MRI
contrast agents has been demonstrated in clinical research
studies for CNS tumor visualization and diagnostic MRI. K.A.,
R. Moats, and J. Frank et al. are currently conducting the neces-
sary preclinical safety and toxicity studies toward achieving FDA
approval of iron labeling for their current NSC-mediated glioma
clinical trial, described below. These advances will probably
have applications for stem cells in other CNS clinical trials.
Choice of Disease Target
First-in-human studies involving NSC transplantation have been
conducted in severe diseases in which the risk/benefit ratio is
favorable. The first two trials involving transplantation of human
NSCs into the brain were both for fatal, rare disorders: neuronal
ceroid lipofuscinosis (NCL) and Pelizeaus-Merzbacher disease
(PMD). Sponsors can benefit from the expedited timeline associ-
ated with fast-track status as well as cost and marketing incen-
tives associated with an orphan drug status to efficiently get into
clinical phase I programs. The Orphan Drug Act defines orphan
drugs as those used to treat rare diseases (less than 200,000people) and it provides grant money, tax credits, and exclusive
marketing rights for 7 years after drug approval. For priority
drugs and biologics, the FDA has an expedited fast-track
program to shorten the new drug application (NDA) review time
from around 12 months to 60 days. In addition, to promote
discovery of treatments for pediatric diseases, the FDA estab-
lished the pediatric rule, which requires assessment of safety
and efficacy in children for select products, compensated by
extending market exclusivity for 6 months (Liu, 2010). Once
human safety is established, both phase II dose-escalation
studies and the inclusion of nonfatal diseases with larger popu-
lation bases may be facilitated. Other sponsors have opted for
initiating clinical testing of their cell product in more prevalent
conditions such as acute spinal cord injury, stroke, ALS, and
brain tumors (Tables 1, 2, and 3).
Outcome Measures
One of the important hurdles in clinical study design for cell
therapy trials is defining endpoints, as this is the measure of
the trial’s failure or success. This is particularly challenging given
the degenerative nature of many target neurological disorders
under consideration and the complexity posed by the rate of
progression and lack of validated surrogate markers of disease.
The overall goal of phase I studies is to assess safety and
feasibility, with the primary objective typically being to determine
the maximum tolerated dose and dose-limiting toxicities.
Secondary objectives are usually correlative studies that will
expand the knowledge gained from conducting the trial. Exam-
ples include imaging studies to determine distribution of the
stem cells, assessment of possible immunogenicity, and postre-
section and/or postmortem histopathological evaluation. Note
that in the absence of noninvasive donor cell tracking, and espe-
cially in diseases in which patients might survive for many years
after transplant, histological measures of donor cell survival,
migration, or differentiation may not be available for decades.
In terms of assessing for toxicity, adverse events are graded
using scales such as the NIH Common Terminology Criteria forNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 601
Table 1. Clinical Trials: Neural Stem Cell-Mediated CNS Regenerative Therapy
Company / Institution
and Trial Site / PI
CNS Regeneration Indication
Health Authority / Regulatory
Agency
Stem Cell Source
and Final Product Delivery Route and Location
Advanced Cell Technology Inc., CA
www.advancedcell.com
Jules Stein Eye Institute at UCLA
PI: S. Schwartz, MD
Phase I/II: Stargardt’s macular
degeneration (juvenile)
Phase I/II: Dry age-related macular
degeneration (AMD)
U.S. Food & Drug Administration,
trial initiation pending
huESC-derived retinal pigmented
epithelial cells (RPEs)
MA09-hRPE
Allogeneic
Direct single subretinal injection
of 50–200,000 RPEs.
California Stem Cell Inc., CA
www.californiastemcell.com
PI: K. Swoboda, MD
Phase I: Spinal muscular atrophy
type I (infants age 2–6 months)
U.S. Food & Drug Administration,
on clinical hold
hESC-derived motor neuron
progenitors (MNPs)
MotorGraft
Allogeneic
Direct multiple injections into
anterior horns of thoracic spinal
cord. Short-term
immunosuppression.
Geron Corp., CA
www.geron.com
Stanford Univ,/Santa Clara Valley
Med Ctr, Palo Alto, CA
PI: G. Steinberg, MD, PhD
Shepard Ctr, Atlanta PI: D. Apple,
MD; Northwestern Univ., Chicago
PI: R. Fessler, MD, PhD; Thomas
Jefferson Univ Hosp, Phil PI:
J. Harrop, PM
Phase I: Neurologically complete
subacute, thoracic spinal cord
injury
ClinicalTrials.gov
ID#NCT01217008
U.S. Food & Drug Administration
huESC-derived oligodendrocyte
progenitor cells
GRNOPC1
Allogeneic
Direct single injection of 2 million
cells (50 mL) into lesioned spinal
cord site (5 mm caudal of injury
epicenter) between T3–T10
segments 7–14 days after injury.
Short-term low-dose Tacrolimus.
Neuralstem, Inc., MD
www.neuralstem.com
PI: E. Feldman MD, PhD, Univ.
Michigan
Emory University ALS Center
PI: J. Glass, MD; N. Boulis, MD
Phase I: Amyotrophic lateral
sclerosis (ALS or Lou Gehrig’s
disease)
ClinicalTrials.gov
ID#NCT01348451
U.S. Food & Drug Administration
Fetal spinal-cord-derived huNSCs
(8 wk gestation) expanded by
epigenetic means with defined
medium (polyclonal)
NSI-566RSC
Allogeneic
Direct multiple injections (100,000
cells per 10 mL injection) into central
gray matter of lumbar spinal cord
segments (L2–L4) in 5 unilateral or
10 bilateral injections (500,000 or
1 million cells total). Long-term
immunosuppression.
NeuroGeneration, Inc., CA
www.neurogeneration.com
Cedars-Sinai Medical Ctr
PI: M. Le´vesque, MD
Site: Los Angeles
Neurosurgical Inst.
PI: M. Le´vesque, MD
Phase I complete: Advanced
Parkinson’s disease
U.S. Food and Drug Administration
Phase II: Advanced Parkinson’s
disease
U.S. Food & Drug Administration,
on clinical hold
huNSCs obtained by needle biopsy
Dissociated cell suspension of
undifferentiated huNSCs and
huNSC-derived neurons
Autologous
Intracerebral unilateral
transplantation into putamen of
6 million cells total (6 deposits).
No immunosuppression.
Results reported in Le´vesque et al.
(2009).
ReNeuron Ltd., Surrey, UK
www.reneuron.com
Instit. of Neurological Sciences,
Glasgow Southern General Hosp,
Glasgow, UK
PI: K. Muir, MD
Phase I: Stable ischemic stroke
Pilot Investigation of Stem Cells
in Stroke (PISCES Trial)
ClinicalTrials.gov
ID#NCT01151124
U.K. Medicines & Health Care
Products Regulatory Agency
Gene Therapy Advisory
Committee
Fetal brain-derived-NSCs
(12 wk gestation) conditionally
immortalized with cmycER
ReN001/CTX0E03
Allogeneic, genetically modified,
clonal
MRI-guided intracerebral injection
of NSCs directly into putamen
adjacent to infarct area.
No immunosuppression.
StemCells, Inc., CA
www.stemcellsinc.com
Univ. California San Francisco, CA
PI: D. Rowitch, MD, PhD
Balgrist University Hospital
University of Zurich, Switzerland
PI: A. Curt, MD
Phase I: Pelizaeus-Merzbacher
disease (PMD)
ClinicalTrials.gov
ID#NCT01005004
U.S. Food & Drug Administration
Phase I/II: Chronic Thoracic
Spinal Cord Injury
ClinicalTrials.gov
ID#NCT01321333
Swissmedic
huCNS-SCs derived from donated
fetal brain tissue
Flow cytometry cell selection
based on CD133 and CD24
expression (CD133+CD24-/lo)
HuCNS-SC
Allogeneic
Phase I: Direct bilateral
intracerebral injections into frontal
white matter (2 per hemisphere).
9 months immunosuppression.
Phase I/II: Direct intraspinal
injections into superior and inferior
margins of thoracic spinal cord
injury (3 and 12 months postinjury).
20 million cells total. 9 months
immunosuppression.
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PerspectiveAdverse Events, version 4.0. The relationship of an adverse
event to study treatment (unrelated, unlikely, possibly, probably,
or definitely related) is assigned based on the known side effects
of the therapy and the patient’s personal medical history. Long-
term follow-up for assessment of late toxicity is important,
particularly in patients with nonfatal conditions, such as spinal
cord injury, who might survive for many years after transplant.
Although we hope to see some indication of therapeutic efficacy
in phase I trials, it is not a prerequisite for the initiation of phase II
studies, which are designed to evaluate efficacy.
The focus of phase II studies should include clinical outcomes
that can be measured and result in a benefit for the patient.
Examples of primary objectives for phase II studies include
assessment of response rate (for example, defined as shrinkage
of tumor in brain cancer studies or improvement in neurologic
function in patients with ALS), time to disease progression and
overall survival. Other examples include improvement of visual
acuity or visual field sensitivity for retinal disorders and transition
to a different American Spinal Injury Association (ASIA) grade for
spinal cord injury. A treatment that demonstrates efficacy in a
phase II study will then typically move on to phase III testing.
Phase III studies are randomized, controlled, multicenter trials
of large numbers of patients for definitive assessment of thera-
peutic efficacy as compared to the standard-of-care.
In summary, defining outcome measures and endpoints is a
complex and sobering exercise. Unfortunately, applicability
and value of such endpoints is oftentimes only evident after
the trial is completed and many millions of dollars have been
spent, highlighting the importance of a thorough and realistic
reflection on endpoint selection.
Survey of CNS Clinical Trials Using Stem Cell Therapy
Therapeutic approaches using NSCs and other stem cell prod-
ucts for the treatment of CNS injury and disease fall into two
broad categories, summarized in Figure 4: (1) regenerative/cell
replacement to promote host tissue repair mechanisms and/or
replace missing or damaged cells, and (2) therapeutic delivery
to provide therapeutic macromolecules (enzymes, cytokines,
neurotrophins, drugs, etc.) for neuroprotection, drug therapy,
and/or stimulation of repair. A third clinically relevant approach
is drug discovery via stem cell-based disease models. In this
section we focus on regulatory approved stem cell-based CNS
clinical trials, summarized in Tables 1, 2, and 3, and include
some preclinical studies that are considered close to IND.
1. Regenerative/Cell Replacement Strategies
Stem cell therapies for neural transplantation and repair aim to
replace damaged cells and/or promote host tissue local neural
repair mechanisms, including neurogenesis, gliogenesis, and
angiogenesis (see Table 1). Human NSCs derived from pluripo-
tent cells or extracted from CNS tissue can be used as undiffer-
entiated cells, relying on the host signals to stimulate their
proliferation and differentiation, or their lineage descendents
can be utilized, such as GRPs. The donor cells are typically deliv-
ered via stereotactic injection into the affected regions. An
alternate means of cell replacement being developed is the
recruitment of endogenous neural progenitor cells from active
adult germinal zones or relatively dormant progenitors elsewherein the CNS, as demonstrated in promising animal models of PD
(Androutsellis-Theotokis et al., 2010).
Spinal Cord Injury
In 2010, two trials were authorized for the use of neural cells to
treat SCI. Geron Corporation (Geron) received FDA clearance to
initiate a phase I trial using hESC-derived oligodendrocyte
progenitors (OPCs), GRNOPC1, in subacute thoracic SCI. This
landmark study represents the first huESC-derived product for
clinical testing. StemCells, Inc. (StemCells) received regulatory
authorization in Switzerland (SwissMedic) to conduct a phase
I/II trial in chronic thoracic SCI using fetal-derived NSCs
(HuCNS-SC). There are important similarities and differences
in the design of each of these studies. Geron’s GRNOPC1
contains hESC-derived OPCs that have demonstrated remyeli-
nating and nerve-growth-stimulating properties leading to resto-
ration of locomotor function in a rat model of acute contusion
SCI (Keirstead et al., 2005). StemCells reported similar findings
in a mouse model of spinal cord contusion injury using HuCNS-
SC (Cummings et al., 2005) and demonstrated their efficacy
beyond the acute injury stage (Salazar et al., 2010). The Geron
phase I study will be conducted in ten patients with neurologi-
cally complete (grade A as defined using ASIA criteria) subacute
thoracic (T3–T10) injuries. Enrolled patients will receive a single
injection of 2 million GRNOPC1 cells into the lesioned site
1–2 weeks after injury. In contrast, StemCells’ HuCNS-SC phase
I/II trial is enrolling patients with complete and incomplete injury
(ASIA A, B, and C) 3 to 12 months (early chronic phase) after
thoracic injury (T2–T11), and patients will receive a dose of
20 million cells.
These trials should shed light on the potential for cell therapy in
SCI. TheGeron trial, as a first test of hESCs, is being awaitedwith
both excitement and trepidation—if the outcome is negative, for
example due to abnormal growths from infusion of cells with high
proliferative potential, then this could be viewed as a blow to the
hESC field. At the same time, we must remember that failures,
however difficult to contemplate, are to be expected during
development of a revolutionary new therapeutic, as was the
case for bone marrow transplantation and the polio vaccine.
Progress is most often made by going from ‘‘bench to beside’’
and back to the bench again with the gained clinical information
applied to an improved second generation product to take
back to the clinic. It is therefore important to educate the
public as to the possible outcomes, both positive and negative,
and the process and timeline for new stem cell therapy
development.
Pelizeaus-Merzbacher Disease
StemCells is conducting a phase I study of pediatric patients
with connatal PMD, a fatal congenital dysmyelination disorder,
using HuCNS-SC. PMD results from a mutation in the X-linked
proteolipid protein (PLP) gene, essential for myelin formation
(Inoue et al., 1999). The more severe form, connatal PMD, typi-
cally presents soon after birth and severe neurological impair-
ments with abnormal mental and physical development lead to
premature death. Enrollment for this trial was completed in early
2011; its primary goal is to determine safety. The potential to
measure donor-derived myelination will also be assessed by
MRI as a secondary endpoint in this study. Other preclinical
studies have explored human glial progenitors for the treatmentNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 603
Table 2. Clinical Trials: Nonneural Stem Cell-Mediated CNS Regenerative Therapy
Company / Institution
and Trial Site / PI
CNS Regeneration Indication
Health Authority / Regulatory
Agency Stem Cell Source and Final Product Delivery Route and Location
Aldagen
www.aldagen.com
Los Angeles Brain and
Spine Insti., CA
PI: G Rappard, MD
Phase II: Postacute ischemic stroke
ClinicalTrials.gov
ID#NCT01273337
U.S. Food & Drug Administration
Adult bone marrow SCs expressing
high levels of ALDH enzyme
ALD-401
Autologous
Intracarotid infusion 13 and 19 days
after unilateral, predominantly
cortical, ischemic nonlacunar
stroke.
Athersys Inc.
www.athersys.com
Phase I: Acute ischemic stroke
U.S. Food & Drug Administration
Trial initiation pending
Adult huBMSC-derived Multipotent
Adult Progenitor Cell (MAPC)
MultiStem
Allogeneic
Intravenous administration 2 days
after stroke.
BrainStorm Cell Therapeutics, Ltd.
www.brainstorm-cell.com
Hadassah Hebrew Univ.
Medical Center, Jerusalem, Israel
PI: D. Karassus, MD, PhD
Phase I/ II: Amyotrophic lateral
sclerosis (ALS or Lou Gehrig’s
disease)
ClinicalTrials.gov
ID#NCT01051882
Ministry of Health, Helsinki
Committee of Hadassah, Israel
Adult bone-marrow-derived
mesenchymal stromal cells
(huMSC) differentiated into cells
secreting neurotrophic factors
(NTF) such as GDNF and BDNF
(MSC-NTF cells)
NurOwn
Autologous
ALS < 6 months: Intramuscular
multiple injections into 24 separate
sites on biceps and triceps muscle /
ALS > 6 months: Intrathecal single
injection into CSF
China Medical University Hospital
www.cmuh.cmu.edu.tw/cmuh/
index.php
China Medical University Hosp.,
Taiwan
PI: S.Z. Lin, MD, DMSci
Phase II: Chronic ischemic stroke
(age 35–70 years)
ClinicalTrials.gov
ID#NCT00950521
Taiwan Department of Health,
China
huPBSCs - peripheral blood
CD34+ SCs
Autologous
Intracerebral implantation of
autologous CD34+ huPBSCs into
patients with chronic middle
cerebral artery infarction in
combination with conventional
treatment.
Duke University
www.dukehealth.org
Duke University Med. Ctr.,
Durham, NC
PI: J. Kurtzberg, MD
Phase I complete: Spastic
cerebral palsy
Phase II: Spastic cerebral palsy
(children age 1–6 years)
ClinicalTrials.gov
ID#NCT01147653
U.S. Food & Drug Administration
huUCBs (banked at birth)
Autologous
Phase I results: Sun et al. (2010)
demonstrating safety and feasibility
Phase II: Intravenous infusion of
10 to 50 million cells/kg of
autologous UCB cells.
Johnson & Johnson
Pharmaceutical Research &
Development, LLC
www.jnjpharmarnd.com
UT Health Science Ctr., Houston
Memorial Hermann Hosp.,
Houston TX
PI: S. Savitz, MD
Phase I: Acute ischemic stroke
ClinicalTrials.gov
ID#NCT01273467
U.S. Food & Drug Administration
huUCB-derived cells
CNTO 0007/42037788
Allogeneic
Intravenous single infusion
administered within 1–5 days
of stroke.
Memorial Hermann Healthcare
System
www.memorialhermann.org
UT Health Science Center,
Houston
PI: J. Baumgarnter, MD
Phase I: Chronic spinal cord
injury (SCI)
(children age 1–15 years)
ClinicalTrials.gov
ID#NCT011328860
U.S. Food & Drug Administration
huBMPCs harvested from subject
6 months–4 years post SCI,
processed for selection of
mononuclear cells
Autologous
Intravenous infusion (single dose) of
autologous huBMPCs administered
within 6 hr of harvest.
SanBio Inc., CA
www.san-bio.com
Stanford Univ. School of Med, CA
PI: G. Steinberg, MD, PhD
UPMC, Pittsburg, PA
PI: D. Kondziolka, MD
Phase I/IIa: Chronic
ischemic stroke
ClinicalTrials.gov
ID#NCT01287936
U.S Food & Drug Administration
Adult mesenchymal SCs
transiently modified with Notch
plasmid
SB623
Allogeneic, transiently modified
MRI-guided stereotactic
intracerebral injections (3 sites)
into peri-infarct subcortical area,
administered at least 6 months
after stroke event.
Stemedica Cell Technologies,
Inc., CA
www.stemedica.com
Univ. California San Diego, CA
PI: M. Levy, MD, PhD FACS
Phase I/II: Chronic ischemic stroke
ClinicalTrials.gov
ID#NCT01297413
U.S. Food & Drug Administration
Donor mesenchymal huBMSCs
Processed for mononuclear cell
selection, and expansion of
colonies to generate a MCB.
Allogeneic
Intravenous administration
(single dose), administered
at least 6 months
after stroke event. No
immunosuppression.
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Company / Institution
and Trial Site / PI
CNS Regeneration Indication
Health Authority / Regulatory
Agency Stem Cell Source and Final Product Delivery Route and Location
TCA Cellular Therapy, LLC
www.tcacellulartherapy.com
TCA Cellular Therapy,
Covington, LA
PI: G. Lasala, MD
Phase I: Amyotrophic
lateral sclerosis
(ALS or Lou Gehrig’s disease)
ClinicalTrials.gov
ID#NCT01082653
U.S. Food & Drug Administration
BM-derived MSCs ex-vivo
expanded up to passage 3
Autologous
Intrathecal single infusion of
50 million cells.
Univ. of Texas Health Science
Center Houston, TX
www.uthouston.edu
Children’s Memorial Hermann
Hospital, Houston, TX
PI: C.S. Cox, Jr., MD
Phase I complete: Acute traumatic
brain injury (TBI) in Children
(age 5–14 years)
ClinicalTrials.gov
ID#NCT00254722
U.S. Food & Drug Administration
Phase I: Chronic TBI in children
(age 18 months–17 years)
ClinicalTrials.gov
ID#NCT01251003
U.S. Food & Drug Administration
huBMPCs harvested from subject
12–30 hr after TBI, processed
for selection of mononuclear
cells (MNCs)
BMMNCs
Autologous
huUCBs (banked at birth,
Cord Blood Registry, Inc.)
Autologous
Intravenous infusion of (6 million
cells/kg body weight) administered
within 48 hr of TBI.
Results: Safety and feasibility
established
Cox et al., 2011.
Intravenous infusion at
6–18 months after TBI event.
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Perspectiveof such congenital dysmyelination disorders on the shiverer
mouse, showing that donor cells substantially myelinate the
host brain, to the point of achieving clinical rescue (Windrem
et al., 2008).
Amyotrophic Lateral Sclerosis
ALS is a progressivemotor neuron disease that also involves glial
cell pathology. In September of 2009, NeuralStem, Inc. received
FDA authorization to conduct a phase I trial in ALS using
adherent cultured, fetal-derived spinal NSCs. Preclinical testing
demonstrated that NSCs transplanted into the lumbar spinal
cord of adult SOD1G93A rats delayed the onset and progression
of the motor neuron disease (Xu et al., 2006). The main objective
of this trial is to evaluate safety of up to ten injections of NSCs in
12 patients in four groups, depending on disease severity.
Q-Therapeutics is working toward an IND for ALS using a human
fetal-derived GRP cell product, and if successful, transverse
myelitis and MS, both involving loss of myelin, are their next
anticipated targets.
Retinal Dystrophy and AMD
Retinal diseases are seen as an important point of entry for CNS
cell therapy because the retina is the most accessible part of
the CNS, contains a relatively small number of cells, and out-
comes of visual function can be accurately monitored. Devas-
tating blinding disorders such as retinitis pigmentosa (RP) and
the highly prevalent AMD lack effective treatments. Over the
past decades, replacement of the outer photoreceptor cell
layer and RPE with fetal tissue has demonstrated transient
visual recovery in animal models and patients leading to
clinical trials of human fetal tissue transplantation for these
disorders (N. Radkte, Clinicaltrials.gov NCT00346060; S. Binder,
Clinicaltrials.gov NCT00401713). Retinal stem cells (RSCs) have
now been isolated from retina tissue and retinal cells generated
from hESCs. When transplanted, adult and ESC-derived retinal
cells incorporate and rescue vision in animal models (Lamba
et al., 2008; Wallace, 2011; West et al., 2009). Although retinal
replacement using RCSs has promise, human trials havenot yet been initiated. HuCNS-SC transplanted into the subreti-
nal space are being moved towards an IND application by
StemCells.
hESCs can be differentiated into RPE and transplantation of
hESC-derived RPE cells (ESC-RPEs) preserves vision in animal
models (Lu et al., 2009). Advanced Cell Technology, Inc. (ACT)
received FDA authorization for studies using hESC-RPEs for
Stargardt’s macular dystrophy in 2010 and for AMD in early
2011. Although the primary defect in Stargardt’s appears in
the photoreceptors, secondary damage to the RPE underlies
the rationale for replacing the RPE to improve cell function,
support the photoreceptors, and delay retinal cell death. The
AMD study will enroll 12 patients to address potential immuno-
genicity, tumorigenicity, and other safety issues for allogeneic
hESC-RPE transplantation into retina. Cells will be injected as
a suspension, and it remains to be seen whether they will incor-
porate into the existing RPE layer to form the polarized epithe-
lium key for its normal function. Nevertheless, it is possible that
a cell suspension could provide beneficial trophic factors even
without epithelialization, although complications that are associ-
ated with RPE cell delamination, such as proliferative vitreoretin-
opathy, will be important to monitor. Related preclinicial work
using hES-RPE is being developed by University College London
in partnership with Pfizer’s London Project, at U.C. Santa Bar-
bara in partnership with Geron under a CIRM disease team grant
and at Hadassah Medical Center, Jerusalem in partnership with
CellCure Neurosciences, Ltd. Tissue-derived stem cells and
adult RPE progenitor cells offer expanded quantities of stan-
dardized cells for replacement of the RPE retinal layer. The latter
is being developed toward an IND for RPE replacement therapy
at the Neural Stem Cell Institute.
Parkinson’s Disease
PD is the most common neurodegenerative movement disorder,
characterized by a loss of dopaminergic (DA) neurons in the
substantia nigra, degeneration in the brainstem, and loss of other
catecholaminergic neurons, which eventually leads to motorNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 605
Table 3. Clinical Trials: Stem Cell-Mediated Therapeutic Delivery to CNS
Company / Institution
and Trial Site / PI
CNS Regeneration Indication
Health Authority / Regulatory
Agency
Stem Cell Source and Final
Product Delivery Route and Location
Biocompatibles International,
PLC
www.biocompatibles.com
The International Neuroscience
Inst. (INI), Hannover, UK
Phase I/II: Acute Hemorrhagic
Stroke
Paul Erlich Institute, Regulatory
Institute of theMinistry of Health,
Germany
Donor adult huMSCs
encapsulated in alginate beads.
CellBeads
Programmed to deliver CM1,
a proprietary version of GLP-1
protein.
Allogeneic, genetically modified
Cellbeads are transplanted
within a retrievable mesh device
directly into injury site and
retrieved after a treatment period
of 14 days.
City of Hope National Medical
Center
www.coh.org
City of Hope, Duarte, CA
PI: J. Portnow, MD
Phase I: Recurrent High Grade
Glioma
Clinical Trials.gov
ID#NSC01172964
U.S. Food & Drug Administration
Recombinant DNA Advisory
Committee (RAC)
Fetal brain-derived (15 wk
gestation)
v-myc immortalized, cytosine
deaminase expressing NSCs
HB1.F3.CD
Allogeneic, genetically modified,
clonal
Direct intracerebral injections
(10 sites) into tumor surgical
resection cavity wall followed
4 days later by 1 week of
treatment with oral 5-FC.
Standard postoperative
dexamethasone tapered as
tolerated.
StemCells Inc, CA
www.stemcellsinc.com
Oregon Health & Science
University Portland, OR
PI: N. Seiden, MD, PhD
Phase I completed: Neuronal
ceroid lipofuscinosis (Batten
disease)
U.S. Food & Drug Administration
Phase Ib: Neuronal Ceroid
(suspended) Lipofuscinosis
ClinicaTrials.gov
ID#NCT01238315
U.S. Food & Drug Administration
huCNS-SCs derived from
donated fetal brain tissue
Cells selected by flow cytometry
based on CD133 and CD24
expression (phenotype
CD133+CD24-/lo)
HuCNS-SC
Allogeneic
Direct bilateral subcortical
injections (3 per hemisphere)
and intraventricular injections (1
per lateral ventrical). 500 million
cells total (3 patients) or 1 billion
cells total (3 patients). 12 months
immunosuppression.
Phase Ib: Direct bilateral
subcortical injections (3 per
hemisphere). 9 months
immunosuppression.
We have made our best effort to include representative regulatory approved stem cell trials for CNS injury and disease and to fact check from original
sources.We apologize for not being able to include all relevant trials. BMSCs = bonemarrow stem cells; BMPCs = bonemarrow progenitor cells; CNS-
SCs = central nervous system stem cells; ESCs = embryonic stem cells; GDNF = glial-derived neurotrophic factor; NSCs = neural stem cells; PBSCs =
peripheral blood stem cells; UCBs = umbilical cord blood cells; BDNF = brain derived neurotrophic factor; GDNF = glial-derived neurotrophic factor;
and hu = human. This description pertains to Tables 1, 2, and 3.
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Perspectivedysfunction and multiple neurological deficits. There is a long
history of fetal cell and tissue transplantation to the projection
sites of these DA neurons, the caudate-putamen, which has
shown some promising results, tempered by the development
of disabling dyskinesias in a number of patients (Hagell et al.,
2002). Concern has also been raised that engrafted cells may
acquire the disease phenotype, as reflected in synuclein aggre-
gates found at autopsy, although the significance of this observa-
tion is debated (Isacson and Mendez, 2010). Nevertheless, for
some PD patients, engrafted fetal-derived cells have given long-
term relief, providing a rational basis for pursuing stem cell grafts
of more uniform, defined cells. Data from such studies indicate
that the relevant cell type is an immature A9 type dopaminergic
neuron (Grealish et al., 2010; Mendez et al., 2005). Methods are
progressing to differentiate hESCs toward production of these
bona fide midbrain DA neurons in sufficiently high numbers for
transplantation, and this is likely to be another early indication
for an hESC-derived cell product. Another approach for PD being
explored by Neurogeneration, Inc. is autologous transplantation
of cultured cells derived from cortical and subcortical tissue,
which is reported to expand in vitro and produce some catechol-
aminergic and gabaergic neurons; although the current trial data606 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.are limited to a single case report, an autologous approach could
be valuable as it avoids immunosuppression.
Stroke
ReNeuron is currently conducting a first-in-human trial for
chronic stable stroke, administering fetal-derived allogeneic
NSCs conditionally immortalizedwith c-mycER into the putamen
adjacent to the infarct area, in order to promote surrounding host
tissue regenerative responses. Preclinical studies in rats with
middle cerebral artery occlusion demonstrated behavioral
recovery in a dose-dependent fashion. NSCs are postulated to
release factors that promote vascular growth and restoration of
blood supply in damaged areas (Stroemer et al., 2009). It will
be important to ascertain how long these cells survive in vivo
and, given that the cell product is an immortalized line, to deter-
mine the safety profile in humans.
Nonneural CNS Stem Cell Treatments
Despite the fact that nonneural sources of stem cells do not
normally generate bona fide neurons or macroglial progeny, a
significant number of CNS clinical trials utilize such cells (see
Table 2). In some cases there is clear rationale and evidence for
nonneural cells alleviating cell loss or disease in the CNS, e.g., in
Neuron
Perspectiverebuilding damaged blood vessels, which can be beneficial to
restore areas of ischemic damage and slow neurodegeneration,
as in murine models of retinal disease (Otani et al., 2004). Another
example is the treatment of Krabbe’s disease (globoid cell leuko-
dystrophy), a fatal lysosomal storage disease (LSD) in children,
where clinical benefit is seen by presymptomatic treatment with
allogeneic umbilical-cord blood stem cells (Escolar et al., 2005).
Correction in this and similar leukodystrophies is mediated by
cellular enzyme replacement therapy through long-term engraft-
ment of donor cells in the brain. In some cases, the transplanted
nonneural stemcellsarepresent in theCNS for a veryshortperiod,
perhaps weeks, but this short-term presence is envisioned to
generate beneficial effectors such as cytokines to ameliorate the
disease process. The use of transient nonneural cells to treat
severe and progressive neurological conditions has been viewed
with considerable skepticism, especially in the scientific commu-
nity, and yet with considerable hope in the patient community.
Now a number of clinical trials have been authorized; indeed,
the regulatoryhurdles for safety, e.g., usingautologousstemcells,
can be easier to surmount, and as they progress, efficacy for
a variety of CNS indications will be determined.
Stroke
SanBio, Inc. is currently in phase I/lla trials with a genetically
modified bone marrow stromal cell product for stroke, SB623,
derived by transfection with a plasmid encoding the human
Notch-1 IntraCellular Domain (NICD) in order to enhance the
cells’ regenerative properties (Yasuhara et al., 2009), a process
that may involve local delivery of soluble trophic factors, deposi-
tion of supportive extracellular matrix, and/or anti-inflammatory
effects. SB623 will be delivered by direct transplantation into
the brain, while other nonneural stem cell clinical trials are using
intravenous infusion. Athersys, Inc. is investigating the adminis-
tration of allogeneic bone marrow-derived multipotent adult
progenitor cells two days after stroke. Aldagen is administering
autologous bone-marrow stem cells into the carotid artery
2–3 weeks after stroke. Aldagen’s cells are selected for expres-
sion of high levels of ALDH enzyme, which enriches for early
hematopoietic cells (Gentry et al., 2007). A similar approach is
being taken by Johnson and Johnson using umbilical-cord-
derived cells. Again, multiple mechanisms have been proposed
for benefit, based on expression of a complex set of factors
that reduce inflammation, protect surrounding brain cells, and
stimulate host angiogenesis.
Cerebral Palsy and Pediatric Traumatic Brain Injury
CP is caused by damage to brain motor areas in utero or during
childbirth, often due to ischemic or hemorrhagic stroke. An
ongoing study at Duke University is testing, in a randomized,
placebo-controlled trial, whether an intravenous infusion of
autologous cord blood, collected and banked at birth, can lessen
the symptoms of children with CP between the ages of 1 and
6 years.
TBI is a major cause of death and disability in young children
and adults. A phase I study completed at the University of Texas
Health Science Center that used harvested bone marrow from
pediatric TBI patients within 30 hr of the injury, followed by intra-
venous infusion of their autologous bone-marrow-derived
mononuclear cells several hours later, has demonstrated safety
and feasibility (Cox et al., 2011).Stimulating Endogenous Stem/Progenitor Cells
AnotherCNS regenerative/cell replacement strategyutilizesdrugs
or cytokines, rather than stemcell transplantation, to stimulate the
patient’sendogenousNSCs.StemCellTherapeutics, for example,
has treated patients with acute ischemic stroke (clinicaltrials.gov
NCT00362414) with a 9 day drug regimen of Beta-hCG plus
Erythropoietin (NTx-265). This drug combination is postulated
to stimulate the patient’s own resident NSCs to reduce brain
damage and promote regenerative processes in the ischemic
brain region. A phase IIb clinical trial was reported in May 2010
to have failed to show efficacy due to unexplained high-level
response in the placebo group as well as the experimental group.
2. Therapeutic Delivery
Stem cells may also be used to deliver therapeutic molecules, in
some cases being modified prior to transplantation for use as
a delivery vehicle to target sites of pathology (see Table 3). The
types of molecules delivered include (1) neurotrophic factors
andcytokines that canenhance regeneration, reducecell damage
and scarring, and promote process outgrowth and connectivity,
(2) enzymes that can replace lost or mutated processes, and (3)
chemotherapeutic agents for novel tumor treatments (Figure 4).
Batten’s Disease
The first FDA-authorized IND using prospectively purified,
ex vivo-expanded NSCs derived from donated fetal human brain
(HuCNS-SC) was sponsored by StemCells for enzyme replace-
ment in the two infantile forms of (NCL; Batten’s Disease),
a rare and fatal lysosomal storage disease in which a genetic
defect leads to abnormal accumulations in lysosomes, neuronal
dysfunction, and loss. The preclinical rationale was established
in the immunodeficient PPT1 knockout mouse that exhibits key
hallmarks of the human disease (Gupta et al., 2001). HuCNS-
SC transplanted into the mouse brain migrated widely and
produced the deficient PPT1 enzyme, leading to reduced stored
material, preservation of hippocampal and cortical neurons, and
a delay in motor coordination loss (Tamaki et al., 2009). The NCL
phase I open-label study enrolled six pediatric patients with
severe infantile and late-infantile NCL in a dose escalation
design: testing a total dose of 500 million cells in the first three
patients and one billion in the next three patients. The surgery,
which involved multiple bilateral HuCNS-SC transplants into
the brain in a single-stage procedure, was well tolerated and
was followed by 12months of immunosuppression. Postmortem
evidence of donor cell survival was obtained in one subject who
expired from the underlying disease 11 months after transplant.
This phase I study, reported in June 2009, was the first to show
human safety data with a NSC product (Steiner et al., 2009). The
follow-on phase 1b study was halted in April 2011 due to inability
to recruit patients matching the enrollment criteria, which is one
of the potential drawbacks when targeting rare diseases.
Brain Tumors: Glioma
NSCs display inherent tumor-tropic properties that can be ex-
ploited for targeted delivery of anticancer agents to tumor cells
(Aboody et al., 2008). This strategy minimizes toxicity to normal
tissues, potentially reducing undesirable side effects. A phase I
clinical trial was initiated in September 2010 by COH for patients
with recurrent high-grade gliomas, who have a median survival
of 3–6 months with currently available treatments. This trial isNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 607
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(HB1.F3.CD), derived from fetal brain telencephalon by immor-
talization with v-myc, enabling effectively unlimited in vitro clonal
expansion (Kim, 2007). The line was further genetically modified
to express cytosine deaminase (CD), an enzyme that converts
the prodrug 5-Fluorocytosine (5-FC) to the active chemothera-
peutic 5-Fluorouracil (5-FU). Safety, stability, and therapeutic
efficacy studies were conducted in orthotopic glioma mouse
models. Based on these and previous studies, it is postulated
that after multiple injections into the tissue surrounding the tumor
resection cavity at the time of surgery, the NSCs will migrate to
residual and invasive brain tumor foci and convert orally admin-
istered 5-FC to 5-FU, preferentially killing surrounding tumor
cells. This dose escalation safety trial will enroll 12–16 patients
and is the first study to explore the safety and feasibility of
a genetically modified allogeneic stem cell-based targeted
cancer therapy using an enzyme/prodrug system in human
patients. A second-generation strategy (funded by CIRM) is in
progress with NSCs engineered to secrete a carboxylesterase
that activates the prodrug CPT-11 (Irinotecan) to the topoiso-
merase inhibitor SN-38, a potent anticancer agent.
3. Drug Discovery and Toxicity Testing via Stem
Cell-Based Disease Models
Another promising application of stem cells is in vitro models to
study diseasemechanisms, screen for drug candidates, and test
drug toxicity. Stem cell-based ‘‘disease in a dish’’ models,
particularly for diseases lacking good animal models, are devel-
oping rapidly and gaining recognition as proof of concept for IND
applications. Improvements in stem cell-based in vitro models,
and the advent of iPSCs expressing patient-specific disease
characteristics, is anticipated to be an increasingly valuable
component of the drug approval process.
HESCs offer an essentially unlimited supply of neural cells,
enabling high-throughput drug screening, and are highly valu-
able for toxicology studies, given that the vast majority of early
drug candidates fail at this step (Fernandes et al., 2009). HESC
lines can be differentiated into specific neural cell types to reca-
pitulate key aspects of disease. Thus, coculture models show
that Super Oxide Dismutase (SOD)-deficient astrocytes secrete
factors that are detrimental to hESC-derived motor neurons
(Di Giorgio et al., 2008; Marchetto et al., 2008). The number of
hESC lines carrying human mutations relevant to CNS disorders
is building, and it would be valuable to collect these in a single,
global, public-accessible registry.
With the discovery of iPSCs, an exciting avenue of research
and potential therapeutic application has opened up because
these cells can model the donor’s disease. iPSC lines generated
from patients suffering from a wide range of CNS disorders are
being generated, an activity that eventually might be better
centralized for banking and distribution, once the methods for
iPSCgeneration, currently improving rapidly, reach a satisfactory
threshold for standardization. Although the development of iPSC
lines for autologous therapeutics has significant hurdles to over-
come, such as cell instability, tumorgenicity, and expense, there
is consensus that disease-specific iPSCs may have tremendous
impact as drug screening platforms for efficacy testing of gene
therapies and drugs (Lengerke and Daley, 2009). In the CNS608 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.arena, iPSC lines have been generated fromALS, Rett syndrome,
retinal gyrate atrophy, and PD patients, allowing the derivation of
cells for follow-on studies (Cundiff and Anderson, 2011; Howden
et al., 2011). For example, it has been demonstrated that iPSC
lines with the LRRK2 mutation show increased expression of
oxidative stress response genes and increased caspase-3
activation and cell death after stress (Nguyen et al., 2011).
While the supply of tissue-derived NSC, RSC, and RPE stem
and progenitor cells is more limited, the miniaturization of drug
screening devices, for example to arrays of tissue printed spots
of a few microns in diameter enabling 1000 point testing on a
single glass slide (Fernandes et al., 2009), will allow these cell
sources to be used more efficiently, and in some cases, they
might better model aspects of a specific disease to accelerate
drug discovery.
Recent Industry Trends and Regulatory Developments
Private industry has traditionally led the translation process,
either sourced in-house or in-licensed from academia. In recent
years, however, interest in and funding for early-stage R&D and
translational research has dramatically declined as industry has
come under increasing financial pressure. While government
agencies such as the NINDS, with a budget of $1.6 billion
($139 million allocated for repair and plasticity and $77 million
for translational research) (NINDS, 2011), commit resources for
early stage research, the vast middle ground of work in preclin-
ical, phase I, and phase II studies are poorly supported, hence
the ‘‘valley of death’’ (Figures 1 and 2).
Recognizing the valley of death, several private foundations
target and support translational research for specific neurolog-
ical diseases (Table S1, available online). Furthermore, alterna-
tive sources of funding such as government agencies and
province- and state-funded initiatives have increased their
commitment to funding translational research. NIH is mobilizing
new translational efforts that include a National Center for
Advancing Translational Sciences (NCATS), anticipated to
launch in the fall of 2011, and an NIH Center for Regenerative
Medicine. NINDS continues to support translational research
with a number of initiatives, including the U-grant mechanisms
(Figure S1), centralized through the recently opened NINDS
Office of Translational Research. An important strategic goal
of NINDS is to improve connections between basic, transla-
tional, and clinical areas and to find new ways to engage the
SBIR and STTR funding programs. A summary of U.S.-based
resources applicable to stem-cell based CNS translation is
given in Table 4, with further details in the Supplemental
Resources.
To further advance translational medicine, NIH has strength-
ened collaborations with the FDA. In February 2010, the FDA
and the NIH announced a collaborative program to accelerate
the pace of drug development. The program established a Joint
NIH-FDA Leadership Council to ensure that regulatory consider-
ations are embedded in the planning of biomedical research and
the regulatory review process is up to date on the latest science.
In addition, $6.75 million will be made available over the next
three years for research focused on improving the methods,
models, and technologies to evaluate safety and efficacy of
medical product development.
Table 4. Resources for CNS Translational Research
Societies/Educational
Examples of courses on drug development:
DIA: http://www.diahome.org/DIAHome/Home.aspx; International Society for Cellular Therapy: http://www.celltherapysociety.org/
PERI: http://www.peri.org/; American Society of Gene and Cell Therapy: http://www.asgct.org/
Barnett: http://www.barnettinternational.com/; European Society of Gene and Cell Therapy: http://www.esgct.eu/
ISSCR: http://www.isscr.org; NIH: http://stemcells.nih.gov
NIH Translational Programs Relevant to CNS
NIH Stem Cell Registry: http://grants.nih.gov/stem_cells/registry/current.htm
NIH Blueprint: http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm
NIH-RAID: http://commonfund.nih.gov/raid/
TRND: http://trnd.nih.gov/
NIMH: http://www.nimh.nih.gov/about/organization/dnbbs/molecular-cellular-and-genomic-neuroscience-research-branch/
drug-discovery-and-clinical-therapeutics-program.shtml
NIDA: http://www.nida.nih.gov/about/organization/DPMCDA/index.html
NIA: http://grants.nih.gov/grants/guide/pa-files/PAR-08-266.html
NCI: http://next.cancer.gov/
NIH Roadmap Molecular Libraries Probe Production Centers: http://mli.nih.gov/mli/mlpcn/
NINDS Office of Translational Research: http://www.ninds.nih.gov/funding/areas/technology_development/index.htm
NIH Center for Regenerative Medicine: http://commonfund.nih.gov/stemcells/
CTSA (Clinical And Translational Science Awards) and the CTSI program: http://www.ctsaweb.org/
NIH Clinical center: http://clinicalcenter.nih.gov/
DOD
Armed Forces Institute of Regenerative Medicine: http://www.afirm.mil/
Regulatory Information
http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/default.htm
Donor eligibility rule: http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/QuestionsaboutTissues/ucm102842.htm.
Centralized IRB
http://www.ncicirb.org/
Listed Trials
http://clinicaltrials.gov/ offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and
conditions
Policy Guidelines and Translational Stem Cell Advocacy
NIH: http://stemcells.nih.gov/policy/2009guidelines.htm
ISSCR: http://www.isscr.org/meetings/index.cfm
Clinical translation guidelines: http://www.isscr.org/clinical_trans/pdfs/ISSCRGLClinicalTrans.pdf
Closer Look: http://www.closerlookatstemcells.org/
Genetics Policy Institute: http://www.genpol.org/
International Society Cell Therapy: http://www.celltherapysociety.org/
California Institute for Regenerative Medicine (CIRM) Disease Team awards: http://www.cirm.ca.gov/for-researchers/current-requests-applications
Faster Cures – Center For Accelerating Medical Solutions: http://www.fastercures.org/
Alliance for Regenerative Medicine: http://www.alliancerm.org/
Progressive IP Policy
Kauffman Institute: http://www.kauffman.org/
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tional research in the area of stem cell biology was a recent
workshop entitled ‘‘Pluripotent Stem Cells in Translation:
Early Decisions’’ (http://www.cvent.com/events/pluripotent-
stem-cells-in-translation-early-decisions/event-summary-942182d
84b084a798f982a3c9df62678.aspx), the first of a planned
series to address moving pluripotent stem cell therapies intothe clinic. Topics discussed included the choice, characteriza-
tion, and biology of pluripotent cells, regulatory requirements
and challenges, and technologies that may facilitate the transla-
tional trajectory.
A particularly noteworthy issue to emerge from this workshop
highlights the FDA Donor Eligibility and Cell Banking Require-
ments. The FDA donor eligibility rule, effective May 25, 2005,Neuron 70, May 26, 2011 ª2011 Elsevier Inc. 609
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evidence of relevant communicable disease agents or diseases.
It is not sufficient that the cellular or tissue-based product is
tested; rather, the original donor must be screened and tested
at the time of tissue recovery, using methods specified by the
FDA (21 CFR 1271.85). The documentation of these tests must
be available when the product is being evaluated by the FDA.
This point cannot be stressed enough: cellular products for clin-
ical use need to meet the FDA donor eligibility rule. For an hESC
line, for example, meeting the requirements of the NIH Human
Embryonic Stem Cell Registry does not ensure that the eligibility
rule has been met (Table 4).Translation in an Academic Environment
Most academic scientists are focused on discovery and creative,
hypothesis-driven science and are solving problems in the lab
at a remarkable pace, creating fertile ground for translation.
However, funding for basic research is getting more difficult to
procure, discouraging young scientists from entering the field
(Rohn, 2011). Also, given that academic success is measured
largely by publications and scholarly awards, there is no easy
path nor career incentives for researchers to accomplish transla-
tion. Furthermore, translational research by its nature entails
a high degree of risk (Figure 2) and requires milestone-based
go/no-go decisions that can mean relinquishing exciting ideas,
which is particularly difficult for basic researchers for whom
ideas are often career identifiers. At the same time, lack of insti-
tutional funding for intellectual property (IP) investment and large
lag times to generate IP, which delays publications, take a toll.
When IP is generated, tech transfer is often inefficient, leaving
IP to languish. Because of these inefficiencies, the number of
products generated from promising basic research is disap-
pointingly low, and researchers and academic institutions are
not sharing in the benefits of productive translation. Bold
solutions are needed—for example, integrating interested
researchers into translational teams so that they would spend
a percentage of their time on a designated translational project,
with commensurate (for time spent) funding for ‘‘blue sky’’
research. This team-based model could work for government-
led funding or within the context of private/public partnerships.
Indeed, as pharmaceutical companies and biotech firms divest
of in-house R&D arms, they are forming strategic academic part-
nerships to both capture IP and support research, and there is
a growing list of companies in the stem cell spacewith CNS inter-
ests. Progress in such team approaches are exemplified by the
NIH U-funding mechanisms and the CIRM disease-team
approach (Table 4).Looking to the Future
Stem cell research is one of the most rapidly developing areas of
science and medicine. The explosive rise in discoveries and
technologies that we see in the basic research labs has yet to
enter the pipeline, and there is an enormous gap between what
we can do at the bench and what we see in the current trials.
While this is a constant source of frustration, the fact is that it
means there is a lot to look forward to, as long as we can
make the process of translation more efficient and affordable.610 Neuron 70, May 26, 2011 ª2011 Elsevier Inc.Currently, the production of specific cell types from stem cells
is conducted differently in individual labs, and in some cases
protocols—typically complex, multistep, and lab-idiosyn-
cratic—can be difficult to repeat. Furthermore, cell output is
measured with relatively rudimentary characterization, raising
concerns that cells produced for clinical trials might not be
bona fide, or stable, or as pure as reported. Developing a greater
understanding of stem and progenitor cell characteristics,
lineage relationships, and single-cell heterogeneity will enrich
our knowledge of how NSCs generate diverse progeny and will
be invaluable for cell characterization and standardization prior
to transplant. It will also aid in identifying new ways to stimulate
endogenous stem and progenitor cells, e.g., with small-molecule
mimics of instructive factors that can lead to controlled in vivo
cell expansion and differentiation.
In terms of cell transplantation for replacement, in addition to
achieving routine and standardized protocols for hundreds of
specific CNS cell types, we anticipate further genetic manipula-
tion of cells prior to transplantation to correct genetically based
diseases or combat the disease process. As well as directed
single-gene excision or supplementation, the ability to alter
networks and pathways via targeting noncoding RNAs and
RNA binding proteins is another exciting avenue with great
potential.
Combination therapies that take into account the specific cell-
cell and cell-matrix interactions that are crucial for CNS function
are an active area of research. One promising option is to employ
scaffolding along with stem cells to provide a substrate and
functionalized artificial niche to direct stem cell behavior (Keung
et al., 2010). Expanding on this idea, CNS repair may be better
achieved by transplantation of functional units that take into
account the interdependence of different CNS cell types, main-
taining key interactions such as endothelial cells and neural cells
to improve graft vascularization, neurons, and glial cells or
different neuron types to replace multiple elements of damaged
circuits, perhaps in three-dimensional arrangements, as dramat-
ically demonstrated by mouse ES-derived eye cup formation
(Eiraku et al., 2011).
Medical advances require a permissive environment to reach
patients, and progress in regulatory science will be critical to
enable successful, efficient translation. Current regulatory para-
digms are of variable stringency depending upon global region
and continue to evolve with scientific progress. Failure to con-
duct trials under strict regulatory oversight can increase risk to
patients and the stem cell field in general. Sobering examples
of isolated reports of adverse events in patients exploring so-
called ‘‘stem cell tourism’’ include a young patient with ataxia
telangiectasia given multiple CNS injections of unpurified and
uncharacterized mixtures of fetal-derived NSCs from multiple
donors over several years that led to donor cell tumor growth
(Amariglio et al., 2009). This emphasizes the need to conduct
such trials under suitable regulatory and ethics oversight.
One controversial issue is that regulatory clearance can be
given in the absence of peer-reviewed publication of the relevant
preclinical data, which precludes full scrutiny and replication of
stem cell culture protocols and results by the broader research
community. It should be underscored that the IND review
process provides in-depth peer-review scrutiny through ad hoc
Table 5. Ideas for More Efficient Translational Research
1. Provide a central resource for advice and guidance—a ‘‘how to’’ for basic researchers entering the translational domain.
2. Facilitate collaborative translational teams of clinicians, advocates, basic researchers, and business experts to promote research that is clinically
needed and compatible with current or anticipated practice and to assess commercial viability.
3. Encourage investigators to consider the practical outcomes of their research and to disclose and patent protect in a timely manner that does not
significantly slow publication or hinder academic freedom.
4. Encourage academic institutes to adopt progressive intellectual property (IP) policies with milestones that if not achieved allow the inventor via
assignment or license to move forward with development.
5. Create centralized institutional review boards (CIRB) for CNS Regenerative Medicine, along the lines of the NCI-CIRB initiative, with access to
expertise to aid and inform local IRBs.
6. Form collaborations with NINDS and patient advocacy groups to facilitate patient recruitment and retention, including pediatrics and rare
diseases.
7. Encourage private foundations to provide greater financial support for translational research.
8. Develop team-based milestone-driven research plans with early go/no-go decisions to keep more funding available for viable projects.
9. Create private/public partnerships centered on CNS regeneration to bring additional funding earlier in the pipeline.
10. Increase public education and awareness of the potential impact and possible outcomes of stem cell CNS clinical trials and the timelines and
costs of therapy development, and encourage public involvement.
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Additionally, regulatory approvals by IRB, IBC, and SCRO sub-
ject the rationale and preclinical data to peer review, as does
the NIH RAC for genetically modified cell products. The issue
of publication is complex as the regulatory approval process
has to take into account confidentiality issues to protect the
sponsor, just as peer review of grant applications preserves
confidentiality. Moreover, if publication were required, the wide
spectrum of scientific journals would complicate distinction
betweenmeritorious preclinical data and those of lesser integrity
and could cause further delays when there are many calls to
speed up the regulatory approval process. It is also worth noting
that amassive body of data is typically submitted in an IND appli-
cation, far exceeding what can be compiled in one or two original
research papers, and adding requirements would increase what
is already a costly undertaking. Notably, while opinions will vary
as to the scientific validity of a specific clinical trial or approach,
the data most important to permit early clinical testing pertain to
safety, which in the US must meet the high standards of the FDA
embodied in statutes and regulations. Nevertheless, given the
early stage of investigating stem cells as a source of neural ther-
apeutics, their supreme complexity and the added challenge
that they are living things that change over time and with
handling and treatment, as much effort as possible toward publi-
cation and the opportunity to replicate data would greatly
strengthen the overall effort by speeding knowledge exchange.
Autologous cell line production, in which a patient’s own
cells are cultured, expanded, and prepared for retransplantation
as a patient-tailored treatment, poses another unique regulatory
issue. From a biological standpoint, autologous transplantation
is advantageous as it may obviate the need for immunosuppres-
sion, with its associated risks. However, the current extensive
requirements for cell manufacture and testing may render such
approaches cost prohibitive. Finding ways to facilitate authoriza-
tion of clinical studies involving autologous transplantation will
greatly benefit advances in individualized regenerativemedicine.
Finally, world-wide adoption of standards for clinical trials,
data collection, and data sharing would expedite the processof identifying proven treatments, which will protect patients,
now growing increasingly savvy regarding regenerative medi-
cine globally, and for whom transparency in shared information,
and honest representation of risks and benefits by the scientific
and medical communities is an essential public service. Efforts
to find new ways to address the regulatory, cost, and funding
issues, from organizations such as the FDA, EMA, NIH, ISSCR,
GPI, and FasterCures (Table 4) that encourage discussion
between stakeholders, are making headway.
Conclusion: Envisioning the Rosetta Stone
Stem cell research and application is opening great opportuni-
ties in CNS regenerative therapies. This survey shows that we
are still at relatively early stages of defining safety for most of
these studies. Nevertheless, encouraged by the progress to
date, and especially by the stupendous strides being made in
preclinical studies, we envision a much more concerted effort
toward translation that would make the process more acces-
sible, integrated into academic and industry settings, and effi-
cient, therefore improving the chance that the health benefits
of research reach patients (Table 5). Moreover, such integrated
efforts would ensure that researchers are rewarded for their
discoveries and skills, bringing more funding into the pipeline
to sustain the entire research enterprise and grounding research
capacity, currently expanding in an unsustainable highly lever-
aged model (Alberts, 2010), by linking it to revenues generated
from real-world productivity. Translation is inordinately expen-
sive and paying for this from the current NIH budget would
severely hinder the basic research effort. Consequently, new
funding streams, such as revenue return from successful trans-
lation, and private/public partnerships are needed. It is impera-
tive to emphasize that the translational process—from bench
to bedside—is founded at the bench, and while necessity is
the mother of invention, creativity flourishes best when one is
not worried about the next vial of stem cell culture medium.
With the growing recognition that translation is a critical goal,
and that we are on the brink of a revolution in CNS regenerative
medicine, resources must continue to be amassed andNeuron 70, May 26, 2011 ª2011 Elsevier Inc. 611
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Perspectivedirections set that will lead toward innovative stem cell-based
CNS therapies and possible solutions to the global and growing
health challenge posed by neurological disorders.
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